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Background: The dipeptidyl peptidase-4 (DPP4) enzyme is a novel adipokine potentially involved in the
development of the metabolic syndrome (MetS). Previous observations demonstrated higher visceral adipose tissue
(VAT) DPP4 gene expression in non-diabetic severely obese men with (MetS+) vs. without (MetS−) MetS. DPP4
mRNA abundance in VAT correlated also with CpG site methylation levels (%Meth) localized within and near its
exon 2 (CpG94 to CpG102) in non-diabetic severely obese women, regardless of their MetS status. The actual study
tested whether DPP4 %Meth levels in VAT are different between MetS− and MetS+ non-diabetic severely obese
subjects, whether variable metabolic and plasma lipid profiles are observed between DPP4 %Meth quartiles, and
whether correlation exists in DPP4 %Meth levels between VAT and white blood cells (WBCs).
Methods: DNA was extracted from the VAT of 26 men (MetS−: n=12, MetS+: n=14) and 79 women (MetS−: n=60;
MetS+: n=19), as well as from WBCs in a sub-sample of 17 women (MetS−: n=9; MetS+: n=8). The %Meth levels of
CpG94 to CpG102 were assessed by pyrosequencing of sodium bisulfite-treated DNA. ANOVA analyses were used to
compare the %Meth of CpGs between MetS− and MetS+ groups, and to compare the metabolic phenotype and
plasma lipid levels between methylation quartiles. Pearson correlation coefficient analyses were computed to test
the relationship between VAT and WBCs CpG94-102 %Meth levels.
Results: No difference was observed in CpG94-102 %Meth levels between MetS− and MetS+ subjects in VAT
(P=0.67), but individuals categorized into CpG94-102 %Meth quartiles had variable plasma total-cholesterol
concentrations (P=0.04). The %Meth levels of four CpGs in VAT were significantly correlated with those observed in
WBCs (r=0.55−0.59, P≤0.03).
Conclusions: This study demonstrated that %Meth of CpGs localized within and near the exon 2 of the DPP4 gene
in VAT are not associated with MetS status. The actual study also revealed an association between the %Meth of
this locus with plasma total-cholesterol in severe obesity, which suggests a link between the DPP4 gene and
plasma lipid levels.
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Deposition of fat preferentially in the abdominal com-
partment is associated with metabolic and inflammatory
alterations often referred to as the metabolic syndrome
(MetS) which considerably increases the risk of type 2
diabetes and cardiovascular disease (CVD) [1]. Both un-
healthy lifestyle and genetic predisposition may influence
lipid storage and adipose tissue metabolism, as well as
their underlying metabolic abnormalities [2]. In a search
aimed at discovering novel candidate genes for MetS, a
gene expression profiling of visceral adipose tissue (VAT)
of non-diabetic severely obese men revealed ~1.85 fold
higher expression of the dipeptidyl peptidase-4 (DPP4)
gene in men MetS+ compared to MetS− [3,4].
The DPP4 (or CD26) glycoprotein is a transmembrane
exoprotease expressed on epithelial cells, importantly in
kidney, intestine and liver, as well as on endothelial cells,
fibroblasts and lymphocytes (i.e. stimulated T-cells, B-
cells and natural killer cells) [5-7]. Since DPP4 is
known to inactivate incretin hormones involved in
glucose-dependent insulin secretion, pharmacological
DPP4-inhibitors have been developed to improve the
treatment of type 2 diabetes [8]. Recently, Lamers et al.
showed that DPP4 can be released from human differ-
entiated adipocytes and can exert autocrine and para-
crine effects by impairing insulin signalling [9]. The
rate of DPP4 release from adipose tissue explants and
soluble DPP4 plasma levels were both higher in se-
verely obese subjects MetS+ as compared to subjects
MetS−. The rate of DPP4 release was also significantly
correlated with MetS phenotypes, such as waist circumfer-
ence, insulin resistance, high-density lipoprotein (HDL)-
cholesterol and triglycerides. The authors suggested that
DPP4 may be a novel biomarker linking obesity to MetS
[9]. It is thus meaningful to consider the DPP4 gene as a
good candidate for MetS development.
A detailed genetic investigation previously conducted
at the DPP4 locus in severely obese individuals revealed
that DPP4 single nucleotide polymorphisms were incon-
sistently associated with plasma triglycerides and total-
cholesterol levels [4]. These polymorphisms were not
significantly associated with DPP4 mRNA abundance in
VAT of non-diabetic severely obese women [4]. How-
ever, DPP4 expression levels were negatively correlated
with cytosine methylation levels of CpG sites (CpGs)
within and near the second exon of the DPP4 gene in
non-diabetic severely obese women [10]. Percentage of
methylation (%Meth) levels of the targeted CpGs were
also positively correlated with plasma HDL-cholesterol
levels in women [10]. In view of these observations, we
hypothesized that the %Meth levels of CpGs within and
near the second exon of the DPP4 gene in VAT are asso-
ciated with MetS susceptibility in non-diabetic severely
obese subjects, which would then suggests its utility as apotential biomarker of MetS. We also hypothesized that
DPP4 methylation levels may be associated with plasma
cholesterol levels, as opposed to DPP4 polymorphisms
[4], and that its methylation in peripheral white blood
cells (WBCs) may serve as a surrogate measure of VAT
methylation at the DPP4 locus.
This study was thus undertaken to test whether the
%Meth levels of the targeted CpGs at the DPP4 locus in
VAT are different between MetS− and MetS+ severely
obese men and women and to verify whether the quar-
tiles of %Meth are associated with metabolic and plasma
lipid profiles. Correlations between DPP4 %Meth levels




The study subjects were severely obese Caucasian men
and women undergoing a biliopancreatic diversion with
sleeve gastrectomy to treat obesity at the Centre de
Recherche de l’Institut Universitaire de Cardiologie et de
Pneumologie de Québec (Québec City, Québec, Canada)
from June 2000 to June 2009. The diagnosis of type 2
diabetes mellitus was made prior to surgery [11]. Body
weight, height, waist circumference, resting systolic and
diastolic blood pressure were measured using standar-
dized procedures [12]. The day of surgery, fasting blood
samples were drawn into EDTA-containing tubes and
centrifuged for WBCs DNA extraction and for plasma
lipid and glucose concentration measurements [12].
VAT from the greater omentum was sampled during the
surgery according to a standardized protocol, as previ-
ously reported [13,14]. All subjects provided a written
informed consent to participate in this study which
received the approval of the Université Laval Ethics
Committee.
Non-diabetic subjects not using any medication to
treat MetS components who were fulfilling minimal
(MetS−: one to two MetS criteria) or maximal (MetS+:
five MetS criteria) MetS criteria were selected. Based on
the criteria from the International Diabetes Federation
definition (IDF) [15], the selected MetS− subjects
were centrally obese (waist circumference ≥88 cm for
women and ≥102 cm for men; USA cutoff values
[16]) with no more than one additional MetS criter-
ion defined hereafter. On the opposite, the selected
MetS+ subjects had to meet the five MetS criteria:
waist circumference ≥88 cm for women and ≥102 cm
for men, fasting plasma glucose ≥5.6 mmol/L, HDL-
cholesterol <1.29 mmol/L for women and <1.03 mmol/L
for men, triglycerides ≥1.7 mmol/L, systolic blood pres-
sure (SBP) ≥130 mmHg or diastolic blood pressure
(DBP) ≥85 mmHg. Postmenopausal women were excluded
from this study in order to avoid potential confounding
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Since there were fewer men meeting the five MetS cri-
teria for the MetS+ group, the selection was extended
to centrally obese men meeting at least three additional
MetS criteria (i.e. total of four to five MetS criteria for
men). To avoid significant differences between groups,
MetS− vs. MetS+ men were matched for age, waist cir-
cumference and smoking. Thus, 28 men and 83 women
were selected for this study. Considering the availability
of VAT samples, we ended up with a total of 26 men
(MetS−: n=12; MetS+: n=14) and 79 women (MetS−:
n=60; MetS+: n=19) for the “VAT experiment”. Relative
to the “WBCs experiment”, 28 non-smoking women
were selected from the 79 women and matched for age
and waist circumference between MetS− and MetS+
groups. Considering the availability of WBCs, we ended
up with a sub-sample of 17 women (MetS−: n=9; MetS+:
n=8) for whom VAT biopsies and WBCs were both avail-
able. Men were not considered for the “WBCs experi-
ment” because of low WBCs availability.
Analysis of DPP4 CpG methylation in VAT and peripheral
WBCs
DNA was extracted from VAT using the DNeasy Blood
& Tissue kit (QIAGEN, Mississauga, Ontario, Canada)





















Figure 1 Location of the 9 CpGs analyzed for their%Meth levels at th
the DPP4 locus were determined relatively to the first adenine (+1) from the A
The DPP4 promoter CpG island was localized using the NCBI Map Viewer pub
and surrounding the 9 CpG sites is located between the 391 and 724 bases a
chr2: 162929768-162930101 on the minus DNA strand as obtained using the
Bold bases represent the exon 2 of the DPP4 gene and arrows are the design
Reference Sequence.Genomic DNA kit (Sigma, St Louis, MO, USA), as
recommended by the manufacturers. DNA extracts were
stored at −80ºC until quantitative methylation analysis
using pyrosequencing technology from QIAGEN [17],
which was performed by the McGill University and Gen-
ome Quebec Innovation Center (MUGQIC) Genotyping
Platform team (Montréal, Québec, Canada). Treatment
of DNA with sodium bisulfite, PCR amplifications and
the pyrosequencing process were performed as previ-
ously described [10]. Primers designed by the MUGQIC
Genotyping Platform team were used to amplify the end
of the DPP4 promoter CpG island (Figure 1a and 1b)
which covered the nine CpGs that have previously been
associated with DPP4 gene expression in VAT as well as
with plasma HDL-cholesterol levels in severely obese
women [10]. The targeted region was amplified in two
fragments using the following primer sequences: first
fragment; forward, 50-Biotin-AAT TGG GAA GTT TTT
TTA GTT A-30, reverse, 50-TAC TAA ATA CTA CTA
CCC TTA TCA CCA TCA TCA C-30, sequencing, 50-
AAT AAA ACA ATT AAA ACT CAA ATC A; second
fragment; forward, 50-AAG AAG GAG TTT GAT TTG
AGT TTT AAT TG-30, reverse, 50-Biotin-TCC CAC
CTA CAA ATC CTA CTA CC-30, sequencing, 50- TGT
TTT AAA TTT ATT GTT TTT GTT TAG-30. PCR
conditions may be obtained upon request. The mean%+495













e DPP4 locus. (a) Delimitation of the 50UTR, exons and CpG island at
TG translation start site (TSS) based on the DPP4 transcript NM_001935.3.
lic database in a previous study [10]. (b) The DNA sequence displayed
fter the TSS of the DPP4 gene. The chromosomal location corresponds to
Human Build 37.3 (http://www.ncbi.nlm.nih.gov/genome/guide/human/).
ed sequencing primers along with the sequencing direction. RefSeq,
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VAT and WBCs was calculated for each subject and used
in the analyses along with individual CpG %Meth levels.
Additionally, DPP4 mRNA abundance in VAT was mea-
sured in the study subjects. Total RNA was extracted from
VAT to generate the cDNA [3] and used for the quantita-
tive real-time reverse transcriptase polymerase chain reac-
tion (qRT-PCR) analysis, as previously described [18].
Amplification efficiencies were validated and normalized
to ribosomal 18S and quantities of target gene were calcu-
lated according to a standard curve. Primers and TaqMan
probes overlapping exons 23 and 24 of the DPP4 gene
(transcript NM_001935) and those for the ribosomal
18S were obtained from Applied Biosystems (DPP4:
Hs00897398_m1; r18S: Hs99999901_s1). Normalized
DPP4 gene expression levels were available for 104 sub-
jects (one excluded outlier; a MetS− woman).
Statistical analysis
Non-normally distributed phenotypes, %Meth levels of
individual CpGs and CpG94-102, as well as DPP4 mRNA
abundance in the 105 subjects selected for the “VAT ex-
periment” were log10- or negative inverse-transformed.
The normality of the distribution of all these variables
was also verified independently in the sub-sample of 17
women selected for the “WBCs experiment” and they
were transformed when needed. The general linear model
(GLM) and the type III sum of squares in SAS were used
to perform ANOVA analyses to compare the phenotype
levels, the %Meth of individual CpGs and CpG94-102, and
DPP4 mRNA abundance between MetS− and MetS+Table 1 Characteristics of the subjects for DPP4%Meth analys
VAT experimen
Phenotypes MetS−
Number of men/women (n) 12/60
Number of MetS criteria (n) 1-2
Smokers (n) 13 (18.1%)
Age (years) 35.3±8.8
BMI (kg/m2) 49.7±8.4
Waist circumference (cm) 131.3±18.7







Mean±SD or n are presented in the table.
All the study subjects were non-diabetic and were not using any medication to trea
Non-normally distributed phenotypes were transformed for the comparison of mea
index (BMI) (−1/(X)), fasting glucose (−1/(X)), triglycerides (−1/(1+X)) and DBP (−1/(X
**P < 0.01.groups while including sex in the model (adjustment for
the sex effect). Associations between DPP4 %Meth levels
and metabolic profile, as well as with plasma lipid levels
were tested by dividing the study subjects into quartiles
based on their CpG94-102 %Meth levels and by comparing
mean phenotype levels between quartiles using ANOVA
analyses as described above while including potential
confounding factors in the model (see the Results sec-
tion for more details about adjustments). When a signifi-
cant effect of CpG94-102%Meth quartiles on phenotypes
was noted, least square means were used to identify
quartiles which are significantly discordant in the cor-
responding phenotype. For the MetS status, logistic
regression analysis was performed to compare MetS−
and MetS+ frequencies between CpG94-102 %Meth
quartiles. Finally, a Pearson correlation coefficient was
computed to test the relationship between VAT and
WBCs CpG94-102 %Meth levels in the sub-sample of 17
women selected for the “WBCs experiment”. The statis-
tically significant P-value was set at 0.05. Statistical ana-
lyses were performed using SAS software version 9.2
(SAS Institute, Cary, NC).
Results
Characteristics of the study subjects in MetS− and MetS+
groups
The characteristics of the subjects are presented in
Table 1 for each type of experiment (VAT and WBCs).
As expected, no significant difference was observed
regarding smoking habit, age and anthropometric values

















n phenotype levels between MetS groups; for the VAT experiment: body mass
)); for the WBCs experiment: triglycerides (log10X) and HDL-cholesterol (log10X).
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and by design, all other MetS-related phenotypes (i.e.
fasting glucose, triglycerides, HDL-cholesterol, SBP and
DBP) differed between MetS− and MetS+ groups when
sex was included in the model (P < 0.01), except for SBP
level in the “WBCs experiment” which was not signifi-
cantly different between MetS groups (P = 0.34).
Comparison of DPP4 %Meth levels between MetS− and
MetS+ groups
The methylation analysis of the nine targeted CpGs
revealed that their %Meth levels were highly correlated
between each other in VAT (r = 0.71−0.99; P < 0.0001),
as well as in WBCs (r = 0.70−0.98; P < 0.0001). Mean %
Meth levels of individual CpGs and CpG94-102 in VAT
were similar in MetS− and MetS+ subjects when sex
was included in the model (P ≥ 0.30) (Figure 2). Similar
results were observed in sex-specific analyses (Men: P ≥
0.62; Women: P ≥ 0.18; data not shown). Further, DPP4
mRNA abundance analysis revealed that the DPP4 gene
was equally expressed (log10-transformed) in the VAT of
MetS− and MetS+ subjects in the present study when
sex was included in the model (P = 0.21), which was also
the case in sex-specific analyses (Men: P = 0.64; Women:
P = 0.06; data not shown). Along with these results, no
difference was observed in the %Meth levels of individ-
ual CpGs and CpG94-102 in WBCs between MetS− and
MetS+ subjects (P ≥ 0.45) (Figure 3).
Associations between DPP4 %Meth quartiles in VAT and
the metabolic and lipid profiles
The study subjects were divided into quartiles (Q)
based on their CpG94-102 %Meth levels in VAT (Q1:


























Figure 2 VAT methylation levels and their comparison between MetS
distributed%Meth levels were transformed for the analysis using the negat
102. Mean±s.e.m. are presented in the figure. MetS−: n=72 subjects; MetS+:
maximum%Meth value. NT, not-tested; s.e.m., standard error of mean.Q4: 21.25%−35.47%; n = 26 in each quartile). As observed
in Table 2, frequencies of MetS− and MetS+ subjects
and mean MetS phenotype levels were similar between
CpG94-102 %Meth quartiles, except for a tendency towards
differences in plasma triglyceride levels between CpG94-102
%Meth quartiles (unadjusted P = 0.07; adjusted P = 0.08;
see legend of Table 2 for details about adjustments).
Regarding plasma lipid levels, a significant association was
observed between CpG94-102 %Meth quartiles and total-
cholesterol concentrations (unadjusted P = 0.03; adjusted
P = 0.04), while no association was found between %Meth
quartiles and mRNA abundance (unadjusted P = 0.13;
adjusted P = 0.13). As observed in Figure 4, subjects with
the lowest CpG94-102 %Meth quartile (Q1) had higher
total-cholesterol concentrations as compared to subjects
in the second (Q2; P = 0.01) and the third (Q3; P = 0.02)
CpG94-102 %Meth quartiles when including age, sex,
smoking and waist circumference in the model. Additional
CpG site-specific analyses revealed that total-cholesterol
and triglyceride levels were significantly different between
CpG98 (P = 0.03) and CpG99 (P = 0.005) %Meth quartiles,
respectively, when including age, sex, smoking and
waist circumference in the model. Globally, a u-shape
relationship was observed where CpG98 %Meth Q3 had
lower plasma total-cholesterol levels as compared
to Q1 (P = 0.007) and Q4 (P = 0.02), and where CpG99
%Meth Q2 had lower plasma triglycerides as compared
to Q1 (P = 0.008), Q3 (P = 0.0009) and Q4 (P = 0.01)
(data not shown).
Correlations between VAT and peripheral WBCs DPP4%
Meth levels
In the premenopausal severely obese women selected for








− and MetS+ groups in severely obese subjects. Non-normally
ive inverse (-1/X) for CpG98, CpG99, CpG100, CpG101, CpG102 and CpG95-





























Figure 3 WBCs methylation levels and their comparison between MetS− and MetS+ groups in severely obese women. Mean±s.e.m. are
presented in the figure. Lower circle: minimum %Meth value; Upper circle: maximum %Meth value. MetS−: n=9 women; MetS+: n=8 women. NT,
not-tested; s.e.m., standard error of mean.
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(r = 0.43, P = 0.09). Regarding CpG site-specific analyses,
%Meth levels of four CpGs in VAT, CpG95 (r = 0.59, P =
0.01), CpG99 (r = 0.55, P = 0.03), CpG100 (r = 0.55, P =
0.03) and CpG101 (r = 0.56, P = 0.02), correlated signifi-
cantly with their %Meth in WBCs.
Discussion
This study revealed that the mean%Meth levels of CpGs
located within and near the second exon of the DPP4
gene (CpG94 to CpG102) were comparable in VAT of
non-diabetic severely obese MetS− and MetS+. Subjects
classified into quartiles based on their CpG94-102 %MethTable 2 Comparison of study subjects’ characteristics betwee
CpG94-102 %Meth quartiles Q1 [11.75−15.74[ Q2 [15.74−18.02[
n = 26 n = 26
MetS phenotypes
MetS− (n = 72) 16 (0.22) 20 (0.28)
MetS+ (n = 32) 10 (0.31) 6 (0.19)
Waist circumference (cm) 135.6 ± 4.2 135.8 ± 4.2
Fasting glucose (mmol/L) 5.36 ± 0.13 5.08 ± 0.11
Triglycerides (mmol/L) 1.73 ± 0.15 1.24 ± 0.10
HDL-cholesterol (mmol/L) 1.37 ± 0.06 1.41 ± 0.06
SBP (mm Hg) 135.7 ± 3.0 138.0 ± 3.7
DBP (mm Hg) 83.0 ± 1.6 81.0 ± 2.3
Other phenotypes
LDL-cholesterol (mmol/L) 3.10 ± 0.13 2.68 ± 0.14
Total-cholesterol (mmol/L) 5.26 ± 0.13 4.65 ± 0.14
DPP4 mRNA in VAT (ratio) 3.92 ± 0.98 5.37 ± 1.24
P-values shown are those obtained for the effect of%Meth quartiles when unadjust
MetS and waist circumference; age, sex, smoking and waist circumference for the o
inverse-transformed for fasting glucose, triglycerides and DBP were used in the analevels had similar characteristics regarding MetS pheno-
types, but were discordant for their plasma total-
cholesterol levels. In a sub-sample of non-diabetic
severely obese premenopausal women, CpG94-102 %Meth
levels in VAT tended to be correlated with their %Meth
levels in WBCs, and %Meth levels of four individual
CpGs (CpG95, CpG99, CpG100 and CpG101) were signifi-
cantly correlated.
The presence of similar DPP4 %Meth levels in VAT be-
tween MetS− and MetS+ subjects rejects the previous hy-
pothesis of a significant difference between the two groups
[3,4]. This observation may potentially be explained by the
absence of differential DPP4 gene expression in VAT of then quartiles of CpG94-102%Meth levels measured in VAT
Q3 [18.02−21.25[ Q4 [21.25−35.47] Pquartiles Pquartiles
n = 26 n = 26 Unadjusted Adjusted
19 (0.26) 17 (0.24) − −
7 (0.22) 9 (0.28) 0.62 0.53
133.3 ± 4.5 138.1 ± 3.7 0.87 0.78
5.26 ± 0.17 5.44 ± 0.20 0.48 0.57
1.61 ± 0.30 1.91 ± 0.29 0.07 0.08
1.37 ± 0.07 1.26 ± 0.06 0.42 0.62
131.7 ± 3.34 131.1 ± 3.5 0.42 0.23
81.9 ± 1.9 81.5 ± 2.3 0.78 0.56
2.75 ± 0.17 3.00 ± 0.19 0.19 0.26
4.72 ± 0.18 5.10 ± 0.19 0.03 0.04
2.99 ± 0.92 3.29 ± 0.81 0.13 0.13
ed or adjusted for potential confounding factors (age, sex and smoking for
ther phenotypes). Log10-transformed for DPP4 mRNA abundance and negative




























n=25 n=25 n=25 n=24
1 2 3 4
Figure 4 Mean total-cholesterol concentrations between CpG94-102
%Meth quartiles in VAT of severely obese subjects. Mean±s.e.m.
are presented in the figure.
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ential expression observed in our previous studies on se-
verely obese men MetS− (n=7) and MetS+ (n=7) [3,4]. It is
actually difficult to clearly explain this discrepancy. Beside
sex, the same subject selection criteria were applied and
the characteristics of male subjects were quite similar as
those from the microarray study [3]. Potential predic-
tors of DPP4 gene expression in VAT were derived from a
complimentary stepwise regression analysis (predictive
variables: age, sex, waist circumference and smoking; data
not shown). Only smoking was significantly associated
with DPP4 mRNA levels in combined men and women
(r2=0.05, p=0.02). The proportion of smokers among the
study subjects was lower as compared to the microarray
experiment where about half of subjects in each group
were smokers [3]. Since frequencies of smokers were not
different between MetS groups in the actual and the
microarray studies, it would thus potentially anneal the
effect of smoking when performing DPP4 mRNA compar-
isons between MetS groups. However, it may not reveal
potential interactions with smoking which would have
induced a greater DPP4 expression among MetS+ men
taking part of the microarray experiment as compared to
male subjects herein. However, to the best of our know-
ledge, no published studies reported that smoking was
related with differential DPP4 gene expression. Added to
this explanation, other subjects’ characteristics which were
not evaluated in our present and previous studies may
have confounded DPP4 gene expression, such as other
DPP4 locus regions under epigenetic regulation [19,20]
via stimulation by cytokines [21,22], the type of cells (e.g.
adipocytes vs. stromo-vascular cells) and their differenti-
ation state [7] within VAT, or even the adipocyte volume
[9]. Further epigenetic and expression studies of the DPP4
gene in cell-specific analyses and with some VAT struc-
tural characterization may potentially help to better
understand the previous DPP4 differential expression
observed in VAT of non-diabetic severely obese men
MetS− and MetS+ [3,4].This study aimed also to test whether the metabolic
and plasma lipid profiles are variable between DPP4
%Meth quartiles in VAT. Apart from different plasma
triglyceride concentrations between CpG99 %Meth quar-
tiles, similar MetS phenotypes were observed between
individual CpGs and combined CpG94-102 %Meth quar-
tiles. In a previous study, positive correlation between
plasma HDL-cholesterol levels and CpG94-102 %Meth
levels in VAT of non-diabetic severely obese women
were observed [10]. However, the actual study did not
reveal any association between HDL-cholesterol concen-
trations and CpG94-102 %Meth levels (Pearson correl-
ation analysis; data not shown) or CpG94-102 %Meth
quartiles, even in sex-specific analyses (data not shown).
Even though the actual and the previous studies [10]
revealed discordant associations between DPP4 %Meth
in VAT and MetS phenotypes, they both underlined an
association between the DPP4 gene and plasma lipid
profile. This observation is further supported by the
presence of significant differences in total-cholesterol
concentrations between CpG94-102 %Meth quartiles in
this study, which are greater in subjects within Q1 as
compared to those within Q2 and Q3, but without any
difference between quartiles in DPP4 mRNA abundance
in VAT. A previous genetic investigation at the DPP4
locus also revealed that two common single nucleotide
polymorphisms were inconsistently associated with the
risk of high triglyceride and cholesterol levels in a multi-
stage study design conducted in severely obese indivi-
duals [4]. These results suggest that both DPP4 %Meth
levels (in VAT) and polymorphisms may influence the
association between the DPP4 gene and the plasma lipid
profile, such as triglycerides and total-cholesterol levels.
This hypothesis may partly explain the inconsistency
seen in the relation between DPP4 genetic and epigen-
etic variations with the plasma lipid profile and with
DPP4 mRNA levels in VAT. Larger studies which would
include both types of variations may increase the chance
to observe genetic associations in future studies. Their
functional impacts on DPP4 gene expression and func-
tion (protein and activity), as well as on DPP4-cleaved
protein levels, would then merit further investigations.
The link between DPP4 and the lipid profile contrasts
with its well-known role on glucose homeostasis. DPP4
has recently been identified in VAT [9] and its function
within this tissue is unknown. A potential link with
plasma triglycerides could be made by the assumption
that DPP4 may inhibits the effect of the incretin hor-
mone glucose-dependent insulinotropic polypeptide on
lipoprotein lipase synthesis and activity in adipocytes
[23,24], which would favor hypertriglyceridemia due to
lower triglyceride hydrolysis as seen in lipoprotein lipase
deficiency [25]. The link between DPP4 in VAT and total-
cholesterol concentrations is somewhat more difficult to
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considering DPP4 action within other tissues and plasma.
Inhibition of DPP4 with vitaglipin has shown to increase
the active form of glucagon-like peptide-1 along with a re-
duction in cholesterol content of chylomicrons after a fat-
rich diet in type 2 diabetic subjects [26], which suggests
an indirect link between DPP4 function and cholesterol
absorption. Tahara et al. have also recently observed a
dose response relationship between DPP4 protein levels
and plasma total-cholesterol concentrations. However, in
a multiple stepwise regression analysis HDL-cholesterol,
but not total-cholesterol, was independently associated
with DPP4 plasma levels in a Japanese population [27].
DPP4 is also recognized as a potential peptidase involved
in the truncation of the neuropeptide Y (NPY), which
would modulate its receptor preference [6]. The common
SNP Leu(7)-to-Pro(7) (T1128C) in the NPY gene has pre-
viously been associated with higher synthesis and secre-
tion of NPY [28], and also with higher total- and LDL-
cholesterol concentrations in serum of obese Finnish and
Dutch subjects [29]. It is unknown how NPY may be
related with serum total-cholesterol concentrations in this
study [29], but these results suggest that an indirect link
between DPP4 and total-cholesterol may exist via the
modulation of NPY function. Furthermore, a recent study
conducted by Zhang et al. also demonstrated an associ-
ation between DPP4 expression and protein levels of two
enzymes involved in cholesterol biosynthesis in melanoma
cells [30], but it is unknown if this relation could be
observed in other tissues, such as in the liver. Hence, these
observations demonstrate few evidences relating the
DPP4 enzyme with the lipid profile, which may be further
clarified in other independent studies.
Currently, there is concern as to whether less-
invasively obtainable human samples (i.e. blood and sal-
iva) would be good surrogates for disease-associated epi-
genetic biomarkers, such concerns being raised because
of the tissue specificity of both epigenetic patterns
[31,32] and disease-associated epigenetic variations [33].
In the actual study, correlations were observed between
the %Meth levels of some targeted CpGs in VAT and
WBCs of a sub-sample of severely obese women. Al-
though cell types expressing DPP4 mRNA in VAT and
WBCs were not investigated in this study, lymphocytes
are suspected to be a common link between the two
compartments because they are DPP4-expressing cells
(i.e. stimulated T-cells, B-cells and natural killer cells)
[5-7] and they are present in both obese VAT [34-36]
and peripheral WBCs. This hypothesis may thus partly
explain the relationship seen between WBCs and VAT
%Meth levels.
One study limitation needs to be outlined, which
regards the heterogeneity of MetS definition to categorize
subjects as being affected or not by obesity-relatedmetabolic complications. To overcome this issue, the
selection of non-diabetic individuals in the extremes of
the MetS definition has been attempted in this study.
However, it may not take into account other metabolic (e.g.
insulin resistance) and VAT physiological (e.g. adipocyte
size, immune cell infiltration) parameters that may better
discriminate those expressing DPP4 at greater levels in their
VAT [3,4]. As previously underlined, further epigenetic and
expression studies at the DPP4 locus would be needed
to clarify what controls VAT DPP4 expression and
whether its methylation levels influence gene expres-
sion in a cell-specific fashion.
In conclusion, this study demonstrated that %Meth of
CpGs localized within and near the exon 2 of the DPP4
gene in VAT are not associated with MetS status. The
actual study also revealed an association between the
DPP4 %Meth with plasma total-cholesterol levels in
severe obesity, which suggests a link between the DPP4
gene and plasma lipid metabolism. Finally, since the %
Meth levels of some of the targeted DPP4 CpGs in VAT
correlated with those observed in WBCs, peripheral
WBCs may potentially be used as a surrogate measure
for DPP4 methylation analysis in further epidemiological
studies in relation with the plasma lipid profile.
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